Towards mRNA therapeutics 2.0
https://t.co/hGncs4wFRN
This new Review discusses progress and insights from clinical studies on mRNA-based drugs, including enzyme replacement therapies, cancer immunotherapies, genome-modifying therapies and immune cell reprogramming therapies
Another major advance vs cancer! @ASCO#ASCO26
Personalized neoantigen mRNA vaccine 5 year follow-up vs metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda)
https://t.co/NadITTYIT2
📢Introducing BiomniBench — the first benchmark focused on evaluating the process, not just the final answer, of AI agents on long-horizon biology research tasks.
We evaluate whether each analysis step is statistically sound and scientifically defensible — just like peer review, where the validity of the process matters, not matching a single ground-truth answer.
Built with first authors from Nature, Cell, and Science papers, BiomniBench captures 100 most ambitious research tasks across disease areas.
Huge headroom for performance, jagged frontiers across tasks, and many more interesting results:
1/🚨More bad news for the Gene Therapy field. Last Wednesday, the FDA raised concerns about life-threatening cases of Cancer - including Leukaemia, in patients that were treated with Bluebird bio’s Skysona - a gene therapy treatment for cerebral adrenoleukodystrophy (CALD). $XBI
“My advice would be to spend less time on finance, spend less time in the conference rooms, less time on PowerPoint, and more time on just trying to make your product as amazing as possible.” — Elon Musk
🎥 @elon_docs
In less than a minute, Washington hit these 3 points:
Point 1: If you don't fail, you're not even trying.
Point 2: To get something you've never had, you have to do something you've never done.
Point 3: Imagine the ghosts of your unfulfilled potential.
https://t.co/ka2DGUy2cw
ODAC on CODEBREAK 200 is a great watch. Polished pharma presentation. I liked the “they feel it and I see it” line. The @FDAOncology critique was a masterclass in analysing bias in open label studies and limitations of BICR. @BTOGORG
#ASCO23 will take us to the agnostic ADC era.
In the just released #HERALD phase 2 trial, 62 patients with 16 different advanced cancer types and detectable HER2 amp on ctDNA received T-DXd.
ORR 56.6%
DCR 90%
Responses in 13 cancer types.
https://t.co/imcjCsliMl
The best way to ensure good code is to have a good organization.
This paper from Microsoft looking at 50M lines of code found that organizational factors were far more powerful in explaining the number of bugs than any technical aspect of the project. https://t.co/4Sxwuug6N5
Here’s the Atlas Venture 2022 Year In Review.
This year, given the 2+ year rollercoaster in the mkts, we start with a deep dive into both the public and private #biotech capital markets, then to the industry overall, closing with an update on Atlas https://t.co/HJ8zEXabyM
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans https://t.co/QiZMo40zQS
New #GBDStudy suggests alcohol consumption carries significant health risks and no benefits for young people; some older adults may benefit from drinking a small amount.
Find out more: https://t.co/nn3V68KNIX @IHME_UW